1. Home
  2. Directory
  3. Florida
  4. Stuart
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1144410713

KARISSA LEIGH RICHARDS ARNP
Prescription History 1144410713
Nurse Practitioner - Women's Health in Stuart, FL

NPI Status: Active since July 30, 2007

Contact Information

3511 SE WILLOUGHBY BLVD
STUART, FL
ZIP 34994
Phone: (772) 221-7789
Fax: (772) 221-8584

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KARISSA LEIGH RICHARDS ARNP, an active Women's Health specialist practicing in Stuart, FL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 184 documented patient claims. Among these therapy options, the most frequently utilized medication is Letrozole, which accounts for 73 claims alone.

Medication Index

A
E
L
T
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 58
30-Day Fills 172.0
Days Supply 5,160
FL State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills135.7
Peer Average Days Supply4,055
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,896.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.70

State Avg Cost Per Claim

$24.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 24
30-Day Fills 68.3
Days Supply 2,049
FL State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills54.4
Peer Average Days Supply1,625
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,468.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$227.87

State Avg Cost Per Claim

$265.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Letrozole

Generic Formulation: LetrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 73
30-Day Fills 192.2
Days Supply 5,760
FL State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills118.7
Peer Average Days Supply3,546
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 49.0% more claims than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,797.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.63

State Avg Cost Per Claim

$29.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 29
30-Day Fills 87.0
Days Supply 2,610
FL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills77.1
Peer Average Days Supply2,302
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,025.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.38

State Avg Cost Per Claim

$34.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like KARISSA LEIGH RICHARDS ARNP provides transparency into local medical care patterns within Stuart, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Women's Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.